NCT07221500
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07221500
Title A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Acronym DAYBreak CLL-201
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Nurix Therapeutics, Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries POL | GBR | FRA


No variant requirements are available.